EczemAid Treats Itch in Adults - FranceMed Pharma

EczemAid® Treats Mild to Severe Itching due to
Mild to Severe Eczema in ages 12+ years - 150ml

EczemAid® Eczema Spray is a Patented, Unique, World's First, Pioneering, Topical, Micro-fine, Registered Medical Device Spray for the instant topical treatment of mild to severe Eczema symptoms for ages 12+ years. Clinically proven to instantly stop mild to severe itching, pain, stinging and achieve long lasting effect. The spray soothes inflamed and weeping skin; reduces redness, scaling and swelling. Free from steroids and antihistamines, suitable for applying on the face, sensitive skin and for use by pregnant women. The spray employs the unique, patented, proprietary "Instant T-CNS Signalling System"™ delivery technology, clinically proven to work within seconds. No known side effects. Repetitive use over time, is clinically proven to treat the Eczema.
The efficacy of this next-generation therapeutic spray is clinically proven to exceed that of the combined treatment using steroids, antihistamines, emollients and cooling lotions or gels for treating the same condition.

Unique Product Attributes of EczemAid® Itching in Adults Eczema, 12+ years

Stops itching within seconds.

Drugs-free, easy spray, instant results.
Calms red, sore, inflamed skin.
Instantly stops irritation and discomfort.
Free from steroids and antihistamines.
No pills, no creams, no mess or fuss.
Above average patient compliance.
Clinically proven claims.

Long lasting effect.
Safe to apply on the face and sensitive skin areas.
High prevalence in all age population.
Safe for pregnant women.
Unique delivery system.
Effectively treats mild to severe conditions.
Repetitive use reduces or treats the underlying condition.
Made in UK.

Click on the image to enlarge

var _gaq = _gaq || []; _gaq.push(['_setAccount', 'UA-7870337-1']); _gaq.push(['_setDomainName', 'none']); _gaq.push(['_setAllowLinker', true]); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); _W.Analytics = _W.Analytics || {'trackers': {}}; _W.Analytics.trackers.wGA = '_gaq'; ;(function(p,l,o,w,i,n,g){if(!p[i]){p.GlobalSnowplowNamespace=p.GlobalSnowplowNamespace||[]; p.GlobalSnowplowNamespace.push(i);p[i]=function(){(p[i].q=p[i].q||[]).push(arguments) };p[i].q=p[i].q||[];n=l.createElement(o);g=l.getElementsByTagName(o)[0];n.async=1; n.src=w;g.parentNode.insertBefore(n,g)}}(window,document,'script','//cdn2.editmysite.com/js/wsnbn/snowday262.js','snowday')); var r = [99, 104, 101, 99, 107, 111, 117, 116, 46, 40, 119, 101, 101, 98, 108, 121, 124, 101, 100, 105, 116, 109, 121, 115, 105, 116, 101, 41, 46, 99, 111, 109]; var snPlObR = function(arr) { var s = ''; for (var i = 0 ; i < arr.length ; i++){ s = s + String.fromCharCode(arr[i]); } return s; }; var s = snPlObR(r); var regEx = new RegExp(s); _W.Analytics = _W.Analytics || {'trackers': {}}; _W.Analytics.trackers.wSP = 'snowday'; _W.Analytics.user_id = '23533560'; _W.Analytics.site_id = '831352365279194172'; // Setting do not track if the GDPR cookie is not present. This is then checked by the snowday initializer // to set tracking decisions. https://github.com/snowplow/snowplow-javascript-tracker/blob/2.6.2/src/js/tracker.js#L1509 window.doNotTrack = document.cookie.indexOf('gdpr-kb') === -1 ? 'yes' : null; var drSegmentsTag = document.getElementById('drSegments'); if (drSegmentsTag) { _W.Analytics.spContexts = _W.Analytics.spContexts || []; var segmentData = JSON.parse(drSegmentsTag.innerText); segmentData.forEach(function(test) { _W.Analytics.spContexts.push({ schema: "iglu:com.weebly/context_ab_segment/jsonschema/1-0-0", data: { test_id: test.name, segment: test.variant, } }); }); } (function(app_id, ec_hostname, discover_root_domain) { var track = window[_W.Analytics.trackers.wSP]; if (!track) return; track('newTracker', app_id, ec_hostname, { appId: app_id, post: true, platform: 'web', discoverRootDomain: discover_root_domain, cookieName: '_snow_', contexts: { webPage: true, performanceTiming: true, gaCookies: true }, crossDomainLinker: function (linkElement) { return regEx.test(linkElement.href); }, respectDoNotTrack: document.cookie.indexOf('gdpr-kb') === -1 }); track('trackPageView', _W.Analytics.user_id+':'+_W.Analytics.site_id, _W.Analytics.spContexts); track('crossDomainLinker', function (linkElement) { return regEx.test(linkElement.href); }); })( '_wn', 'ec.editmysite.com', true ); (function(jQuery) { try { if (jQuery) { jQuery('div.blog-social div.fb-like').attr('class', 'blog-social-item blog-fb-like'); var $commentFrame = jQuery('#commentArea iframe'); if ($commentFrame.length > 0) { var frameHeight = jQuery($commentFrame[0].contentWindow.document).height() + 50; $commentFrame.css('min-height', frameHeight + 'px'); } if (jQuery('.product-button').length > 0){ jQuery(document).ready(function(){ jQuery('.product-button').parent().each(function(index, product){ if(jQuery(product).attr('target') == 'paypal'){ if (!jQuery(product).find('> [name="bn"]').length){ jQuery('<input>').attr({ type: 'hidden', name: 'bn', value: 'DragAndDropBuil_SP_EC' }).appendTo(product); } } }); }); } } else { // Prototype $$('div.blog-social div.fb-like').each(function(div) { div.className = 'blog-social-item blog-fb-like'; }); $$('#commentArea iframe').each(function(iframe) { iframe.style.minHeight = '410px'; }); } } catch(ex) {} })(window._W && _W.jQuery); window._W.isEUUser = false; window._W.showCookieToAll = "";